日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Assessing economic investment required to scale up bariatric surgery capacity in England: a health economic modelling analysis

评估英格兰扩大减肥手术能力所需的经济投资：一项卫生经济模型分析

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-084356
Baker-Knight, James; Pournaras, Dimitri J; Mahawar, Kamal; Welbourn, Richard; Li, Yuxin; Sharma, Yuvraj; Guerra, Ines; Tahrani, Abd
发表日期：2024
文献求助 收藏

Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation

评估东亚人群肥胖相关并发症的健康和经济负担：在日本核心肥胖模型中应用风险方程并进行模型验证

期刊:
影响因子:
doi:10.1136/bmjph-2023-000302
Tatsuno, Ichiro; Gerlier, Laetitia; Olivieri, Anamaria-Vera; Baker-Knight, James; Lamotte, Mark
肥胖
代谢
发表日期：2024
文献求助 收藏

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China

注射疗法在肥胖症和2型糖尿病治疗中的弊端：英国、加拿大和中国普通人群的偏好

期刊:European Journal of Health Economics
影响因子:3
doi:10.1007/s10198-022-01470-w
McEwan, Phil; Baker-Knight, James; Ásbjörnsdóttir, Björg; Yi, Yunni; Fox, Aimee; Wyn, Robin
糖尿病
肥胖
代谢
发表日期：2023
文献求助 收藏

The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs

瑞典2型糖尿病控制不佳给纳税人带来的公共经济负担：超越医疗成本的视角

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.14667
Kotsopoulos, Nikolaos; Connolly, Mark P; Willis, Michael; Nilsson, Andreas; Ericsson, Åsa; Baker-Knight, James
糖尿病
代谢
发表日期：2022
文献求助 收藏

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression

采用多水平网络Meta回归对司美格鲁肽2.0 mg与度拉糖肽3.0 mg和4.5 mg的间接治疗效果进行比较

期刊:Journal of Clinical Endocrinology & Metabolism
影响因子:5.1
doi:10.1210/clinem/dgab905
Lingvay, Ildiko; Bauer, Robert; Baker-Knight, James; Lawson, Jack; Pratley, Richard
发表日期：2022
文献求助 收藏

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

在英国，评估每周一次注射1毫克司美格鲁肽与25毫克恩格列净治疗2型糖尿病患者的成本效益

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-020-00989-6
Capehorn, Matthew; Hallén, Nino; Baker-Knight, James; Glah, Divina; Hunt, Barnaby
糖尿病
代谢
发表日期：2021
文献求助 收藏

The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System

糖尿病成人胰岛素相关低血糖的经济负担：从意大利医疗保健系统的角度进行的分析

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-018-0418-0
Parekh, Witesh; Streeton, Sophie E; Baker-Knight, James; Montagnoli, Roberta; Nicoziani, Paolo; Marchesini, Giulio
代谢
糖尿病
免疫/内分泌
发表日期：2018
文献求助 收藏

The Economic Burden of Insulin-Related Hypoglycemia in Spain

西班牙胰岛素相关低血糖症的经济负担

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-017-0285-0
Parekh, Witesh; Hoskins, Nicki; Baker-Knight, James; Ramirez de Arellano, Antonio; Mezquita Raya, Pedro
免疫/内分泌
发表日期：2017
文献求助 收藏

Erratum to: The Economic Burden of Insulin-Related Hypoglycemia in Spain

勘误：西班牙胰岛素相关低血糖症的经济负担

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-017-0293-0
Parekh, Witesh; Hoskins, Nicki; Baker-Knight, James; Ramirez de Arellano, Antonio; Mezquita Raya, Pedro
免疫/内分泌
发表日期：2017
文献求助 收藏